Key facts
- This page summarizes Joseph A. Byrne's Form 3 filing for CEN BIOTECH INC.
- 0 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 03 Jun 2021, 08:41.
Joseph A. Byrne - 19 Apr 2021 Form 3 Insider Report for CEN BIOTECH INC
- Reporting relationship
- President, Director
- Issuer ticker
- N/A
- Reported as of
- 19 Apr 2021
- Net transaction value
- $0
- SEC form
- 3
- Accepted by SEC
- 03 Jun 2021, 08:41:02 UTC
- Prior SEC filing
- 28 May 2021
- Source filing
- View source filing
- Reporting owner signature
- /s/ Joseph Byrne
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Joseph A. Byrne filed Form 3 for CEN BIOTECH INC on 03 Jun 2021.
Change
- Previous filing in this sequence was filed on 28 May 2021.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Official SEC source
View source filing
Ownership activity is grounded in SEC Form 3 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
CENBF
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 1,364,894
- Date
- 19 Apr 2021
- Ownership
- Direct
- Footnotes
- F1
CENBF
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 164,000
- Date
- 19 Apr 2021
- Ownership
- By Spouse
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
CENBF
holding
Derivative
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 19 Apr 2021
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 76,123
- Exercise price
- $1.60
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
Joseph Byrne (the "Reporting Person") was appointed to his positions with CEN Biotech, Inc. (the "Issuer") on April 19, 2021 and owned 1,362,894 shares of the Issuer's common stock at such date.
Footnote F2
The Reporting Person also beneficially owns a convertible note with 76,123 shares issuable upon conversion of same.